摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Isostegan | 61038-90-2

中文名称
——
中文别名
——
英文名称
Isostegan
英文别名
(13R)-3,4,5-trimethoxy-11,18,20-trioxapentacyclo[13.7.0.02,7.09,13.017,21]docosa-1(22),2,4,6,15,17(21)-hexaen-10-one
Isostegan化学式
CAS
61038-90-2;70051-17-1;70051-18-2;72258-40-3;72258-54-9;72657-29-5;72657-64-8;76250-31-2;92283-76-6;92283-77-7;96744-76-2;96744-77-3;96744-78-4;96744-79-5
化学式
C22H22O7
mdl
——
分子量
398.412
InChiKey
YIIRKVZAEAXDAD-CFMCSPIPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    624.0±55.0 °C(Predicted)
  • 密度:
    1.299±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    29
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    72.4
  • 氢给体数:
    0
  • 氢受体数:
    7

文献信息

  • Process To Obtain Synthetic And Semi-Synthetic Lignan Derivatives, Their Antiparasitic Activities And Corresponding Pharmaceutical Formulations, Including The Therapeutic Method Using Said Lignan For The Treatment Of Parasitosis
    申请人:Silva Marcio Luis Andrade e
    公开号:US20080194678A1
    公开(公告)日:2008-08-14
    A process to obtain synthetic and semi-synthetic derivatives of lignans, especially dibenzylbutyrolactonic, tetrahydrofuranic, aryltetralynic, furofuranic and dibenzocyclooctanic lignans obtained by means of partial synthesis and/or full synthesis or also by isolation from plant extracts. It refers to a process to obtain synthetic and semi-synthetic derivatives of (−)-cubebin, such as: (−)-O-acetylcubebin; (−)-O-methylcubebin; (−)-O—N,N-(dimethylamino-ethyl)-cubebin; (−)-hinokinin; (−)-6,6′-dinitroinokinine; (−)-O-benzylcubebin; (−)-6,6′-diaminoinokinin, (−)-6,6′-dinitroinokinin, as well as to obtain dibenzocyclooctanic lignans from dibenzylbutyrolactoinic lignans by means of structural modifications in the positions 7, 7′, 8, 8′, 9′ and in the aromatic rings (introduction and/or substitution of functional groups such as: —OH, —CO 2 H, —CO 2 CH 3 , —NO 2 , —NH 2 , —OCH 3 , —OAc, —SO 2 CH 3 , —SO 2 NH 2 , prenyl and halogens) is provided. A therapeutic method using the derivatives is also provided.
  • [EN] PROCESS TO OBTAIN SYNTHETIC AND SEMI-SYNTHETIC LIGNAN DERIVATIVES, THEIR ANTIPARASITIC ACTIVITIES AND CORRESPONDING PHARMACEUTICAL FORMULATIONS, INCLUDING THE THERAPEUTIC METHOD USING SAID LIGNAN FOR THE TREATMENT OF PARASITOSIS<br/>[FR] PROCEDE PERMETTANT D'OBTENIR DES DERIVES SYNTHETIQUES ET SEMI-SYNTHETIQUES DE LIGNANES, LEURS ACTIVITES ANTIPARASITAIRES, PREPARATIONS PHARMACEUTIQUES CORRESPONDANTES, ET METHODES THERAPEUTIQUES UTILISANT LESDITS LIGNANES POUR TRAITER LA PARASITOSE
    申请人:FUNDACAO DE AMPARO A PESQUISA
    公开号:WO2007009201A2
    公开(公告)日:2007-01-25
    [EN] The invention refers to a process to obtain synthetic and semi-synthetic derivatives of lignans, especially dibenzylbutyrolactonic, tetrahydrofuranic, aryltetralynic, furofuranic and dibenzocyclooctanic lignans obtained by means of partial synthesis and/or full synthesis or also by isolation from plant extracts. It refers to a process to obtain synthetic and semi-synthetic derivatives of (-)-cubebin, such as: (-)-O-acetylcubebin; (-)-O-methylcubebin; (-)-O-N,N-(dimethylamino-ethyl)-cubebin; (-)-hinokinin; (-)-6,6'-dinitroinokinine; (-)-O-benzylcubebin; (-)-6,6'-diaminoinokinin, (-)-6,6'-dinitroinokinin, as well as to obtain dibenzocyclooctanic lignans from dibenzylbutyrolactoinic lignans by means of structural modifications in the positions 7, 7', 8, 8', 9' and in the aromatic rings (introduction and/or substitution of functional groups such as: -OH, -CO2H, -CO2CH3, -NO2, -NH2, -OCH3, -OAc, -SO2CH3, -SO2NH2, prenyl and halogens). The invention also refers to a therapeutic method, since the substances described are used in the manufacture of medicine that presents antiparasitic activity.
    [FR] La présente invention se rapporte à un procédé permettant d'obtenir des dérivés synthétiques et semi-synthétiques de lignanes, en particulier de lignanes dibenzylbutyrolactoniques, tétrahydrofuraniques, aryltétralyniques, furofuraniques et dibenzocyclooctaniques, qui sont obtenus par synthèse partielle et/ou totale ou également par isolation à partir d'extraits végétaux. L'invention se rapporte aussi à un procédé permettant d'obtenir des dérivés synthétiques et semi-synthétiques de la (-)-cubébine, tels que : la (-)-O-acétylcubebine ; la (-)-O-méthylcubébine ; la (-)-O-N,N-(diméthylamino-éthyl)-cubébine ; la (-)-hinokinine ; la (-)-6,6'-dinitroinokinine ; la (-)-O-benzylcubébine ; la (-)-6,6'-diaminoinokinine ; et la (-)-6,6'-dinitroinokinine. L'invention permet également d'obtenir des lignanes dibenzocyclooctaniques à partir de lignanes dibenzylbutyrolactoiniques, à l'aide de modifications structurelles aux positions 7, 7', 8, 8', 9' et dans les cycles aromatiques (introduction et/ou substitution de groupes fonctionnels tels que -: -OH, -CO2H, -CO2CH3, -NO2, -NH2, -OCH3, -OAc, -SO2CH3, -SO2NH2, prényle et halogènes). L'invention a également trait à une méthode thérapeutique, lesdites substances pouvant servir à fabriquer un médicament qui présente une activité antiparasitaire.
查看更多

同类化合物

鬼臼脂毒酮 鬼臼毒素-4-O-葡萄糖苷 鬼臼毒素 鬼臼毒素 苦鬼臼毒素 脱氧鬼臼毒素 磷酸依托泊甙 盾叶鬼臼素 澳白木脂素2 澳白木脂素1 替尼泊苷 托尼依托泊苷 去氧鬼臼毒素 克立米星C 他氟泊苷 丙氨酸,N-(羧基甲基)-(9CI) alpha-盾叶鬼臼素 alpha-依托泊苷 [(5R,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-8-氧代-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-5-基]丁酸酯 TOP-53二盐酸盐 NK-611盐酸盐 5,8,8a,9-四氢-9-羟基-5-(3,4,5-三甲氧基苯基)-(5R,5aR,8aR,9S)-呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5aH)-酮 4’-去甲鬼臼毒素 4’-去甲基表鬼臼毒素-Β-D-葡萄糖甙 4-{[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]氨基甲酰}苯基乙酸酯 4,6-O-苄叉-Β-D-葡萄糖甙鬼臼毒素 4'-去甲基表鬼臼毒素 4'-O-脱甲基-4-((4'-(1'-苯甲基哌啶基))氨基)-4-脱氧鬼臼毒 4 ’-去甲去氧鬼臼毒素 3-羟基-4H-吡喃-4-酮 3-氨基-N-[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]苯酰胺 2’-O-没食子酰基金丝桃甙 2(3H)-硫代酰苯,3-乙基二氢-3-(1-甲基乙基)-(9CI) 2'-氯依托泊苷 1-羟基-17-氧杂五环[6.6.5.0~2,7~.0~9,14~.0~15,19~]十九碳-2,4,6,9,11,13-六烯-16,18-二酮(non-preferredname) (8aR,9S)-9-[[(2R)-7,8-二羟基-2-(2-噻吩基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5S,5aS,8aR,9R)-5-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基-苯基)-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-8-酮 (5S,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-5-(4-羟基苯基)硫烷基-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二噁唑-8-酮 (5R,5aR,8aS,9S)-9-[(4-氨基苯基)氨基]-5-(4-羟基-3,5-二甲氧苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-6(5aH)-酮盐酸(1:1) (5R,5aR,8aR,9R)-9-羟基-10-甲氧基-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(4-甲氧基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(2-羟基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-8-羰基-9-(3,4,5-三甲氧苯基)-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基乙酸酯 (5R,5aR,8aR,9R)-5-(4-乙氧基-3,5-二甲氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-5-(3,5-二甲氧基-4-丙氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R)-5,8,8ab,9-四氢-5b-(3,4,5-三甲氧基苯基)呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5abH),9-二酮 (5-氯吡啶-3-基)丙酸甲酯 (3aS,4S,9R,9aR)-4-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基苯基)-6,7-二甲氧基-3a,4,9,9a-四氢-3H-萘并[3,2-c]呋喃-1-酮 (3aR,4S,9R,9aR)-4,6,7-三羟基-9-(4-羟基-3,5-二甲氧苯基)-3a,4,9,9a-四氢萘并[2,3-c]呋喃-1(3H)-酮 (1R,3aS,4R,6aR)-4-(1,3-苯并二氧戊环-4-基)-1-(1,3-苯并二氧戊环-5-基)-3,3a,4,6a-四氢-1H-呋喃并[3,4-c]呋喃-6-酮